NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Callio Therapeutics

Callio Therapeutics

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://calliotx.com/

Last Round

Series A

Mar 3, 2025

Total Funding Raised

$187M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Callio Therapeutics is a biotechnology company that develops next-generation, multi-payload antibody-drug conjugates (ADCs) for cancer therapy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

antibody-drug conjugatesADCdual-payload ADConcology therapeuticscancer drug discoverybiotechtargeted cancer therapyclinical-stage biotechHER2-targeted therapydrug resistanceAI-augmented drug discoveryprecision medicinecomputational biologynext-gen biologics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Callio Therapeutics Comparables

Compare Callio Therapeutics with similar companies based on industry and business-model similarity.

Callio Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Canwell Biotech Ltd.
86%
Eli Lilly and Company
83%
NetTargets
78%

Callio Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 3, 2025

Key People

Founding team and executive leadership

Jerome Boyd-Kirkup

Chief Scientific Officer Co-Founder

Founding Team

Kiran Asarpota

Chief Operating Officer

Executive Team

Callio Therapeutics Investors

Notable investors and investment history

Callio Therapeutics investors
InvestorRounds
Omega FundsSeries A
SEEDS CapitalSeries A
ClavystBioSeries A
EDBISeries A
Norwest Venture PartnersSeries A
Frazier Life SciencesSeries A
Novo HoldingsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 26, 2026

    Monthly visitors increased 135% MoM, reaching 6.3K.

  • May 16, 2026

    Monthly visitors grew 2373% MoM, from 108 to 2.7K.

Callio Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Callio Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Callio Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range19
Year Founded2025
Last FundingMar 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.